NovaBridge Biosciences (NBP) 12th Annual Cantor Fitzgerald Global Healthcare Conference summary

Company vision and strategy

• Focuses on accessing innovation, advancing clinical programs, and disciplined capital allocation to bring differentiated therapies to patients globally.

• Operates a business development team in China and a clinical team in Maryland, targeting therapies across Asia-Pacific and worldwide.

• Utilizes flexible capital pathways and subsidiary structures to accelerate asset development.

Givastomig program highlights

• Givastomig, a bispecific Claudin 18.2/4-1BB agent, is advancing in first-line gastric cancer with phase I-B and phase II studies ongoing.

• Phase III trial is planned for initiation by year-end 2026, with potential for accelerated approval and Fast Track designation.

• Data show improved ORR and progression-free survival over standard immunochemotherapy, with a favorable safety profile and broader patient eligibility compared to zolbetuximab.

• ESMO update will present mature data from nearly 70 patients, including efficacy and safety across multiple doses.

• Expansion into pancreatic and biliary tract cancers is underway, potentially doubling the eligible patient population.

Differentiation and safety considerations

• Givastomig targets patients with low Claudin 18.2 expression, expanding access beyond current therapies.

• Demonstrates manageable safety profile, with localized gastritis as a notable but expected side effect in combination therapy.

• Avoids complex side effects seen with ADCs and T-cell engagers, supporting use in frontline settings.

• Ongoing education for physicians and robust phase III design aim to optimize safety and efficacy.